Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + BP102 ± SHR2554 in Metastatic Colorectal Cancer
NCT06679673Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, zeprumetostat in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
retlirafusp alfazeprumetostat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06679673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679673.